Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia – topic of research paper in Medical engineering. Download scholarly article PDF and read for
Mechanism of Action | ARIKAYCE® (amikacin liposome inhalation suspension)
Presented by : Mina Assaad Metry Under the supervision of : Prof. Dr. Seham Hafez. - ppt download
Drug as Percentage of Total Dose Deposited in Nebulizer and Ventilator... | Download Table
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the T | DDDT
Amikacin injection or inhalation antibiotic uses, dose & side effects
Inhaled Amikacin Using AeroEclipse® XL BAN (Breath Actuated Nebulizer)
Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease | Antimicrobial Agents and Chemotherapy
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia | NEJM
PDF) Pharmacokinetics of High Dose Nebulized Amikacin in Mechanically Ventilated Healthy Subjects.
Frontiers | Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
Neonatal Intensive Care Unit Amikacin Dosage Protocol | Download Scientific Diagram
Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials | Scientific Reports
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis - ScienceDirect
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the PARI eFlow® Technology - Medicine
ARIKAYCE Dosage & Rx Info | Uses, Side Effects
In vitro efficiency of Amikacin Inhale, a novel drug-device delivery system | Critical Care | Full Text
Mechanism of Action | ARIKAYCE® (amikacin liposome inhalation suspension)
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease | European Journal of Drug Metabolism and Pharmacokinetics